Sign in
CompletedEarly phase 1

The Effects of Sedatives on Tobacco Use Disorder Version 2

Key facts

Who runs it
Wake Forest University Health Sciences
Where
Winston-Salem, United StatesSee the site
Trial code
Status
Completed
Phase
Early phase 1
People taking part
20 people enrolled
Started
31 Jan 2023
Ended
10 Dec 2025
Type of study
Interventional, 12 groups
Treatments tested
  • Ketamine
  • Midazolam
  • Dexmedetomidine
  • Saline
Record updated
1 April 2026

Who can take part

Age
21 years to 55 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Smokes cigarettes daily for at least 2 years
  • Afternoon expired breath carbon monoxide at least 5 ppm or morning urinary cotinine at least 100 ng/ml
  • Negative urine drug screen for psychoactive drugs and negative breath alcohol

Who cannot take part

  • Use of drugs that would interact with study drug or increase risk of adverse events
  • Have an unstable medical condition or stable medical condition that would interact with study drug or participation, including chronic pulmonary disease, coronary artery disease, current brain tumor, current increased intracranial pressure or impaired consciousness
  • History of serious head trauma or neurological disorder (e.g., seizure disorder)
  • Have any of the following: hypertension (i.e., systolic >140 mm Hg and/or diastolic >90 mm Hg on three separate measures; systolic >170 or diastolic > 110 on any occasion), pre-existing severe gastrointestinal narrowing (pathologic or iatrogenic)
  • Among women, pregnancy or lactation

Where in United States

  • Wake Forest University Health SciencesWinston-Salem, United States

About the trial

What the trial wants to find out

Double-blind, placebo-controlled, randomized mechanistic clinical trial to test an intravenous dose of either ketamine, midazolam, dexmedetomidine, or a placebo (saline) on cigarette smoking behavior, craving, and neural effects.

The 12 groups in the trial

  • Saline first injection; ketamine second injectionTreatment being tested

    Subjects in this arm will receive a single intravenous infusion of placebo at the first injection visit and a single intravenous infusion ketamine at the second injection visit.

    Treatment: Ketamine and Saline

  • Saline first injection; midazolam second injectionTreatment being tested

    Subjects in this arm will receive a single intravenous infusion of placebo at the first injection visit and a single intravenous infusion midazolam at the second injection visit

    Treatment: Midazolam and Saline

  • Saline first injection; dexmedetomidine second injectionTreatment being tested

    Subjects in this arm will receive a single intravenous infusion of placebo at the first injection visit and a single intravenous infusion dexmedetomidine at the second injection visit.

    Treatment: Dexmedetomidine and Saline

  • Ketamine first injection; Saline second injectionTreatment being tested

    Subjects in this arm will receive a single intravenous infusion of ketamine at the first injection visit and a single intravenous infusion placebo at the second injection visit.

    Treatment: Ketamine and Saline

  • Ketamine first injection; midazolam second injectionTreatment being tested

    Subjects in this arm will receive a single intravenous infusion of ketamine at the first injection visit and a single intravenous infusion midazolam at the second injection visit.

    Treatment: Ketamine and Midazolam

  • Ketamine first injection; dexmedetomidine second injectionTreatment being tested

    Subjects in this arm will receive a single intravenous infusion of ketamine at the first injection visit and a single intravenous infusion dexmedetomidine at the second injection visit.

    Treatment: Ketamine and Dexmedetomidine

  • Midazolam first injection; Saline second injectionTreatment being tested

    Subjects in this arm will receive a single intravenous infusion of midazolam at the first injection visit and a single intravenous infusion placebo at the second injection visit.

    Treatment: Midazolam and Saline

  • Midazolam first injection; ketamine second injectionTreatment being tested

    Subjects in this arm will receive a single intravenous infusion of midazolam at the first injection visit and a single intravenous infusion ketamine at the second injection visit.

    Treatment: Ketamine and Midazolam

  • Midazolam first injection; dexmedetomidine second injectionTreatment being tested

    Subjects in this arm will receive a single intravenous infusion of midazolam at the first injection visit and a single intravenous infusion dexmedetomidine at the second injection visit.

    Treatment: Midazolam and Dexmedetomidine

  • Dexmedetomidine first injection; Saline second injectionTreatment being tested

    Subjects in this arm will receive a single intravenous infusion of dexmedetomidine at the first injection visit and a single intravenous infusion placebo at the second injection visit.

    Treatment: Dexmedetomidine and Saline

  • Dexmedetomidine first injection; ketamine second injectionTreatment being tested

    Subjects in this arm will receive a single intravenous infusion of dexmedetomidine at the first injection visit and a single intravenous infusion ketamine at the second injection visit.

    Treatment: Ketamine and Dexmedetomidine

  • Dexmedetomidine first injection; midazolam second injectionTreatment being tested

    Subjects in this arm will receive a single intravenous infusion of dexmedetomidine at the first injection visit and a single intravenous infusion midazolam at the second injection visit.

    Treatment: Midazolam and Dexmedetomidine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
1 April 2026